Back

Bempedoic acid for LDL-cholesterol management in patients with and without diabetes: insights from the MILOS study

29 August 2026 (09:15 - 09:45)
Organised by: Logo
Congress Presentation Part of: Therapeutic advancements in lipid-lowering pharmacotherapy Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Thomas M Stulnig

Clinic Hietzing, Vienna (Austria)

3 More presentations in this session

Presentation thumbnail
Understanding discrepancies in trial-level surrogacy of LDL-cholesterol reduction for cardiovascular risk: a methodological appraisal and updated meta-regression
Doctor G. Chen (Zurich, CH)
Abstract Slides
Presentation thumbnail
An inclisiran-based treatment strategy reduces the need for therapy escalation to achieve low-density lipoprotein cholesterol goals: Exploratory findings from the VICTORION-Difference trial
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
Real-world efficacy of bempedoic acid: early insights from the BEMPENET Italian Registry
Doctor C. Cotticelli (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
Therapeutic advancements in lipid-lowering pharmacotherapy

The Event

Event poster

ESC Congress 2026

29 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of bempedoic acid alone and combined with ezetimibe on ldl-cholesterol reduction: graphical evidence and retrospective analysis of a real-world clinical cohort
24 April 2026
thumbnail
Congress Presentation
Diabetes and contemporary treatment of chronic heart failure in a large real-world heart failure population
29 June 2021
thumbnail
Congress Presentation
High levels of small dense LDL cholesterol potentiate the risk of poor glycemic management for long-term prognosis in patients with stable coronary artery disease
1 September 2025
thumbnail
Congress Presentation
Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources